A Journey through ω-3 Supplements: Future Perspectives for Precision Nutrition

Iker Jauregibeitia¹, Kevin Portune¹, Javier Amezaga¹, Itziar Tueros¹ and Sara Arranz^1,

¹Basque Research and Technology Alliance (BRTA), Parque Tecnológico de Bizkaia, Astondo Bidea, Edificio 609, 48160 Derio (Bizkaia), Spain

Cite this paper:
Iker Jauregibeitia, Kevin Portune, Javier Amezaga, Itziar Tueros and Sara Arranz. A Journey through ω-3 Supplements: Future Perspectives for Precision Nutrition. Journal of Food and Nutrition Research. 2020; 8(10):556-560. doi: 10.12691/jfnr-8-10-3

Abstract

Increasing evidence has shown that fatty acids play a key factor in nutrition and health. Despite the well described health benefits associated to the omega-3 fatty acids (ω-3 FA) intake from epidemiological and clinical trials, controversial results are found from some clinical trials regarding the effect of ω-3 FA supplementation to handle certain diseases. In this review, we provide orientation for the reader to understand the importance of a personalized recommendation of the ω-3 polyunsaturated fatty acid supplementation based on a precision nutrition approach. We begin by reviewing the metabolic relevance of ω-3 fatty acids and then discuss the current state of ω-3 fatty acid supplements regarding their indications, regulation, variety from brand to brand, adverse effects and the need to implement a personalized supplementation. We conclude with future perspectives for practitioners and general guidance on precision nutrition.

Keywords:
lipidomics omega 3 fatty acids precision nutrition health

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, Thomas PR, et al. Dietary supplement use in the United States, 2003-2006. J Nutr. 2011; 141(2): 261-6.
[2]	Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl Health Stat Report. 2015; 10(79): 1-16.
[3]	Bailey RL, Gahche JJ, Miller PE, Thomas PR, Dwyer JT. Why US adults use dietary supplements. JAMA Intern Med. 2013; 173(5): 355-61.
[4]	Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Journal. 2012; 10(7): 2815.
[5]	Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev. 2010; 68(5): 280-9.
[6]	Lauritzen L, Brambilla P, Mazzocchi A, Harslof LB, Ciappolino V, Agostoni C. DHA Effects in Brain Development and Function. Nutrients. 2016; 8(1).
[7]	Mori TA. Omega-3 fatty acids and cardiovascular disease: epidemiology and effects on cardiometabolic risk factors. Food Funct. 2014; 5(9): 2004-19.
[8]	Gleissman H, Johnsen JI, Kogner P. Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp Cell Res. 2010; 316(8): 1365-73.
[9]	Calder PC. n-3 fatty acids, inflammation and immunity: new mechanisms to explain old actions. Proc Nutr Soc. 2013; 72(3): 326-36.
[10]	Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain Behav Immun. 2011; 25(8): 1725-34.
[11]	Burdge GC. Metabolism of alpha-linolenic acid in humans. Prostaglandins, leukotrienes, and essential fatty acids. 2006; 75(3): 161-8.
[12]	Vessby B, Gustafsson IB, Tengblad S, Boberg M, Andersson A. Desaturation and elongation of Fatty acids and insulin action. Ann N Y Acad Sci. 2002; 967: 183-95.
[13]	Childs CE, Romeu-Nadal M, Burdge GC, Calder PC. Gender differences in the n-3 fatty acid content of tissues. Proc Nutr Soc. 2008; 67(1): 19-27.
[14]	Koletzko B, Lattka E, Zeilinger S, Illig T, Steer C. Genetic variants of the fatty acid desaturase gene cluster predict amounts of red blood cell docosahexaenoic and other polyunsaturated fatty acids in pregnant women: findings from the Avon Longitudinal Study of Parents and Children. The American journal of clinical nutrition. 2011; 93(1): 211-9.
[15]	Bolton-Smith C, Woodward M, Tavendale R. Evidence for age-related differences in the fatty acid composition of human adipose tissue, independent of diet. European journal of clinical nutrition. 1997; 51(9): 619-24.
[16]	Simopoulos AP. An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity. Nutrients. 2016; 8(3).
[17]	Jandacek RJ. Linoleic Acid: A Nutritional Quandary. Healthcare. 2017; 5(2).
[18]	Chilton FH, Dutta R, Reynolds LM, Sergeant S, Mathias RA, Seeds MC. Precision Nutrition and Omega-3 Polyunsaturated Fatty Acids: A Case for Personalized Supplementation Approaches for the Prevention and Management of Human Diseases. Nutrients. 2017; 9(11).
[19]	Levy L, Tedstone A. UK Dietary Policy for the Prevention of Cardiovascular Disease. Healthcare. 2017; 5(1).
[20]	The omega-3 fatty acids and the cardiovascular system: Nutritional benefits and claims. French Agency for Food, Environmental and Occupational Health Safety, 2003.
[21]	Belgium Superior Health Council. Dietary guidelines for the Belgian adult population 2019; Available from: https://www.health.belgium.be/en/advisory-report-9284-fbdg-2019#anchor-36076.
[22]	Kromhout D, Spaaij CJ, de Goede J, Weggemans RM. The 2015 Dutch food-based dietary guidelines. European journal of clinical nutrition. 2016;70(8):869-78.
[23]	Nutrient reference values for Australia and New Zealand including recommended dietary intakes. Australia and New Zealand National Health and Medical Research Council, 2006.
[24]	Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Journal. 2010; 8(3): 1461.
[25]	U.S. Department of Health and Human Services and U.S. Department of Agriculture. Dietary Guidelines for Americans. 2015-2020 [December 2015]; 8:[Available from: https://health.gov/dietaryguidelines/2015/resources/2015- 2020_Dietary_Guidelines.pdf.
[26]	Fats and fatty acids in human nutrition. Proceedings of the Joint FAO/WHO Expert Consultation. November 10-14, 2008. Geneva, Switzerland: Ann Nutr Metab. 2009; 55(1-3): 5-300.
[27]	Patterson AC, Stark KD. Direct determinations of the fatty acid composition of daily dietary intakes incorporating nutraceuticals and functional food strategies to increase n-3 highly unsaturated fatty acids. J Am Coll Nutr. 2008; 27(5): 538-46.
[28]	Papanikolaou Y, Brooks J, Reider C, Fulgoni VL, 3rd. U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003-2008. Nutr J. 2014; 13(31): 1475-2891.
[29]	Ian Givens D, Gibbs RA. Current intakes of EPA and DHA in European populations and the potential of animal-derived foods to increase them. Proc Nutr Soc. 2008; 67(3): 273-80.
[30]	European Food Safe Authority EFSA. EU Register of nutrition and health claims made on foods. 2016.
[31]	Hilleman D, Smer A. Prescription Omega-3 Fatty Acid Products and Dietary Supplements Are Not Interchangeable. Manag Care. 2016; 25(1): 46-52.
[32]	Ritter JC, Budge SM, Jovica F. Quality analysis of commercial fish oil preparations. Journal of the science of food and agriculture. 2013; 93(8): 1935-9.
[33]	Jackowski SA, Alvi AZ, Mirajkar A, Imani Z, Gamalevych Y, Shaikh NA, et al. Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety. Journal of nutritional science. 2015; 4(4).
[34]	Albert BB, Cameron-Smith D, Hofman PL, Cutfield WS. Oxidation of marine omega-3 supplements and human health. Biomed Res Int. 2013; 464921(10): 30.
[35]	Shahidi F, Zhong Y. Lipid oxidation and improving the oxidative stability. Chemical Society Reviews. 2010; 39(11): 4067-79.
[36]	Sciotto C, Mjos SA. Trans isomers of EPA and DHA in omega-3 products on the European market. Lipids. 2012; 47(7): 659-67. Epub 2012/05/09.
[37]	Menounou G, Giacometti G, Scanferlato R, Dambruoso P, Sansone A, Tueros I, et al. Trans Lipid Library: Synthesis of Docosahexaenoic Acid (DHA) Monotrans Isomers and Regioisomer Identification in DHA-Containing Supplements. Chem Res Toxicol. 2018; 31(3): 191-200.
[38]	Brouwer IA, Wanders AJ, Katan MB. Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans--a quantitative review. PloS one. 2010; 5(3): 0009434.
[39]	Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007; 370(9602): 1829-39.
[40]	Bendsen NT, Christensen R, Bartels EM, Astrup A. Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies. European journal of clinical nutrition. 2011; 65(7): 773-83.
[41]	Brouwer I. Effect of trans-fatty acid intake on blood lipids and lipoproteins: a systematic review and meta-regression analysis. Geneva: World Health Organization; 2016.
[42]	Ulven SM, Kirkhus B, Lamglait A, Basu S, Elind E, Haider T, et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. 2011; 46(1): 37-46.
[43]	Dyerberg J, Madsen P, Moller JM, Aardestrup I, Schmidt EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins, leukotrienes, and essential fatty acids. 2010; 83(3): 137.
[44]	Corella D, Ordovas JM. The role of omics in precision nutrition: strengths and weaknesses. Nutr Hosp. 2018; 35(Spec No4): 10-8.
[45]	Hernando Boigues JF, Mach N. The effect of polyunsaturated fatty acids on obesity through epigenetic modifications. Endocrinol Nutr. 2015; 62(7): 338-49.
[46]	Rudkowska I, Paradis A-M, Thifault E, Julien P, Barbier O, Couture P, et al. Differences in metabolomic and transcriptomic profiles between responders and non-responders to an n-3 polyunsaturated fatty acids (PUFAs) supplementation. Genes & Nutrition. 2013; 8(4): 411-23.
[47]	Stanley EG, Jenkins BJ, Walker CG, Koulman A, Browning L, West AL, et al. Lipidomics Profiling of Human Adipose Tissue Identifies a Pattern of Lipids Associated with Fish Oil Supplementation. J Proteome Res. 2017; 16(9): 3168-79.
[48]	Visioli F. Lipidomics to Assess Omega 3 Bioactivity. J Clin Med. 2015; 4(9): 1753-60.
[49]	Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, McCabe E, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. The Journal of clinical investigation. 2011; 121(4): 1402-11.
[50]	Stegemann C, Pechlaner R, Willeit P, Langley SR, Mangino M, Mayr U, et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation. 2014; 129(18): 1821-31.
[51]	Ferreri C, Chatgilialoglu, C. Membrane Lipidomics for Personalized Health. Chichester, UK: John Wiley & Sons; 2015.
[52]	Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018; 18(7).
[53]	Shaikh NA, Tappia PS. Why are there inconsistencies in the outcomes of some omega-3 fatty acid trials for the management of cardiovascular disease? Clinical Lipidology. 2015; 10(1): 27-32.
[54]	Bowen KJ, Harris WS, Kris-Etherton PM. Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits? Curr Treat Options Cardiovasc Med. 2016;18(11):016-0487.